At a glance
ClinicalIndex Comparison RecordN/ACompleted· 161 enrolled
Drug / intervention
Afatinibdrug
Likely dose
Afatinib 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational Study of GIOTRIF (Afatinib) for First Line Therapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR)-Mutations.
In Brief
An observational study evaluating Afatinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 161 participants across 1 site.
Detailed Summary
This observational study will investigate the efficacy, safety, tolerability and symptom control of GIOTRIF (Afatinib) in daily routine first-line therapy in patients with locally advanced or metastatic NSCLC harboring EGFR-mutations. Eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with GIOTRIF in first line according to the local label, will be followed up for approximately 24 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesGermany
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartMar 2014
Primary CompletionDec 2018
TodayJul 2026
First PostedJan 28, 2014
Enrollment StartMar 5, 2014
Primary CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 12.4 years ago
Interventions
Afatinibdrug
50, 40, 30 or 20 mg